SEC Form 4 · accession 0001209191-18-043633
Skye Bioscience, Inc. · SKYE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas A Cesario
Officer — CFO and Secretary
Period of report
Jul 23, 2018
Accepted (ET)
Jul 23, 2018 · 5:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516551
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 23, 2018 | A | 643,501 | $0.00 | A | 643,501 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $0.245 | Jul 23, 2018 | A | 1,195,073 | A | — | Jul 23, 2028 | Common Stock | 1,195,073 | 1,195,073 | D |
Explanation of responses
- F1100% of the restricted stock award shall vest and be deliverable on April 23, 2020.
- F225% of the total number of shares subject to the option shall vest and become exercisable on July 23, 2018, and the remaining 75% of the total number of shares subject to the option shall vest and become exercisable 1/33rd on each of the next 33 months thereafter.